Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1868 1
1956 2
1969 1
1973 1
1975 4
1977 4
1978 2
1979 4
1980 6
1981 5
1982 7
1983 4
1984 6
1985 14
1986 10
1987 11
1988 12
1989 11
1990 9
1991 12
1992 10
1993 9
1994 24
1995 17
1996 13
1997 13
1998 4
1999 18
2000 22
2001 28
2002 23
2003 21
2004 18
2005 27
2006 15
2007 31
2008 14
2009 14
2010 15
2011 11
2012 7
2013 9
2014 9
2015 10
2016 11
2017 14
2018 14
2019 20
2020 16
2021 15
2022 20
2023 23

Text availability

Article attribute

Article type

Publication date

Search Results

609 results

Results by year

Filters applied: . Clear all
Page 1
Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Moreau P, et al. Among authors: stephenson t. N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35661166 Clinical Trial.
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Usmani SZ, et al. Among authors: stephenson t. Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10. Lancet. 2021. PMID: 34388396 Clinical Trial.
The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis.
O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, Karamchandani U, Simms-Williams N, Cassambai S, Ardavani A, Wilkinson TJ, Hawthorne G, Curtis F, Kingsnorth AP, Almaqhawi A, Ward T, Ayoubkhani D, Banerjee A, Calvert M, Shafran R, Stephenson T, Sterne J, Ward H, Evans RA, Zaccardi F, Wright S, Khunti K. O'Mahoney LL, et al. Among authors: stephenson t. EClinicalMedicine. 2022 Dec 1;55:101762. doi: 10.1016/j.eclinm.2022.101762. eCollection 2023 Jan. EClinicalMedicine. 2022. PMID: 36474804 Free PMC article.
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Girgis S, Wang Lin SX, Pillarisetti K, Verona R, Vieyra D, Casneuf T, Fink D, Miao X, Chen Y, Stephenson T, Banerjee A, Hilder BW, Russell J, Infante J, Elsayed Y, Smit J, Goldberg JD. Girgis S, et al. Among authors: stephenson t. Blood Adv. 2023 Feb 28;7(4):644-648. doi: 10.1182/bloodadvances.2022007625. Blood Adv. 2023. PMID: 36006441 Free PMC article. No abstract available.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y. Girgis S, et al. Among authors: stephenson t. Target Oncol. 2022 Jul;17(4):433-439. doi: 10.1007/s11523-022-00893-y. Epub 2022 Jun 24. Target Oncol. 2022. PMID: 35749004 Free PMC article. Clinical Trial.
Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study.
Stephenson T, Pinto Pereira SM, Shafran R, de Stavola BL, Rojas N, McOwat K, Simmons R, Zavala M, O'Mahoney L, Chalder T, Crawley E, Ford TJ, Harnden A, Heyman I, Swann O, Whittaker E; CLoCk Consortium; Ladhani SN. Stephenson T, et al. Lancet Child Adolesc Health. 2022 Apr;6(4):230-239. doi: 10.1016/S2352-4642(22)00022-0. Epub 2022 Feb 8. Lancet Child Adolesc Health. 2022. PMID: 35143770 Free PMC article.
Long COVID (post-COVID-19 condition) in children: a modified Delphi process.
Stephenson T, Allin B, Nugawela MD, Rojas N, Dalrymple E, Pinto Pereira S, Soni M, Knight M, Cheung EY, Heyman I; CLoCk Consortium; Shafran R. Stephenson T, et al. Arch Dis Child. 2022 Jul;107(7):674-680. doi: 10.1136/archdischild-2021-323624. Epub 2022 Apr 1. Arch Dis Child. 2022. PMID: 35365499 Free PMC article.
Continuously advancing quality care.
Molloy A, Stephenson T, Marshall M. Molloy A, et al. Among authors: stephenson t. Arch Dis Child. 2022 Feb;107(2):107-108. doi: 10.1136/archdischild-2020-321394. Epub 2021 Jan 17. Arch Dis Child. 2022. PMID: 33455905 No abstract available.
609 results